In addition, as expected due to the different penetrance of TARDBP pathogenic variants in the two sexes,22 female patients were underrepresented in the TARDBP-ALS cohort (8, 24.2%) compared with controls (55, 42.6%). This evidence concerns the gene TARDBP and amyotrophic lateral sclerosis.